Bristol-Myers Squibb and ZymoGenetics to Present Final Phase Ib Data at AASLD 2009AASLD 2009

Bristol-Myers Squibb Company and ZymoGenetics, Inc. have announced that final results from a Phase 1b clinical trial in patients with hepatitis C (HCV) treated with PEG-Interferon lambda, a new class of interferon, in combination with ribavirin will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting October 30-November 3, in Boston.

"Bristol-Myers Squibb is pleased to partner with ZymoGenetics in the development of this promising new investigational interferon," said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer, and president, Research and Development of Bristol-Myers Squibb. "This is a collaboration that is focused on innovative science that will potentially translate into important new options for patients living with hepatitis C."

"We are pleased to present the first set of data in patients living with hepatitis C on this promising new interferon," said Douglas E. Williams, Ph.D., Chief Executive Officer of ZymoGenetics. "This is the first complete data set to emerge following the announcement of our collaboration with Bristol-Myers Squibb. We look forward to a continuation to our productive partnership with Bristol-Myers Squibb as we work to bring PEG Interferon Lambda to hepatitis C patients as rapidly as possible."

In a release, the Companies noted event details:

The poster presentation will take place Tuesday, November 3, 8 a.m. to 1 p.m. and will include final results from the study, including cohorts of both relapsed and treatment-naive patients, and will confirm the activity of the interferon lambda across a broad range of doses. The abstracts are being published today and will be available at the AASLD website, aasld.org.

PEG-Interferon lambda Phase 1b Final Results Poster

Title: A Phase 1b Dose-ranging Study of 4 Weeks of PEG-Interferon (IFN) Lambda (PEG-rIL-29) in Combination with Ribavirin (RBV) in Patients with Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

Abstract: 1591

Presenter: Andrew Muir, M.D., MHS, Clinical Director, Hepatology, Duke University School of Medicine

Date: Tuesday, November 3,

Time: 8 AM - 1 PM

About PEG-Interferon lambda

PEG-Interferon lambda (IL-29) is a novel type 3 interferon in development for hepatitis C. The native human protein Interferon lambda is generated by the immune system in response to viral infection.

Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering medicines that help patients prevail over serious diseases.

ZymoGenetics discovers, develops and commercializes its products independently, in collaboration with partner companies or through out-licensing.

((Comments on this story may be sent to health@closeupmedia.com))

Related terms: ceo, clinical, executive, health, infection, medicine, partnership, president, products, research and development, science, trial, university